Gyrus Capital has successfully raised €600 million for a continuation vehicle to support the expansion of Essential Pharma, enhancing its capacity to deliver niche pharmaceuticals and address rare diseases.

Information on the Target

Essential Pharma is a significant international specialty pharmaceutical company committed to delivering low-volume, clinically differentiated, niche pharmaceuticals across key therapeutic areas. Serving over 70 countries, the group has established itself as a vital partner to healthcare providers for over two decades, facilitating access to medicines for underserved patient populations and addressing critical clinical unmet needs.

The company is focused on several therapeutic areas, including central nervous system disorders, gastroenterology, ophthalmology, and rare diseases. Essential Pharma employs a strategic approach that emphasizes portfolio optimization and targeted mergers and acquisitions (M&A) to enhance its market position while ensuring a continuous supply of essential medicines.

Industry Overview in Switzerland

Switzerland boasts a robust pharmaceutical and biotechnology industry, recognized globally for its innovation and quality. The Swiss pharma sector is characterized by its combination of established multinational corporations and a vibr